Cidara Therapeutics Inc (NASDAQ: CDTX) stock suffered a major decline of -11.7% on 1/13/25. The shares closed at $21.19. NORMAL trading volume accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -22.4% during the last week.
Current PriceTarget Research Rating
Cidara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment